Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis

被引：0
|
作者：
Kaulen, Leon D. [1 ,2 ,3 ,4 ]
Karschnia, Philipp [1 ,5 ,6 ]
Doubrovinskaia, Sofia [2 ,3 ,4 ]
Abramson, Jeremy S. [7 ]
Martinez-Lage, Maria [8 ]
Shankar, Ganesh [9 ]
Choi, Bryan D. [9 ]
Barnes, Jeffrey A. [7 ]
El-Jawahri, Areej [7 ]
Hochberg, Ephraim P. [7 ]
Johnson, P. Connor [7 ]
Soumerai, Jacob D. [7 ]
Wick, Wolfgang [2 ,3 ,4 ]
Maus, Marcela V. [7 ,10 ]
Chen, Yi-Bin [7 ]
Frigault, Matthew J. [7 ,10 ]
Dietrich, Jorg [1 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Neurooncol, Dept Neurol,Canc Ctr, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA
[2] Heidelberg Univ, Dept Neurol, Univ Hosp Heidelberg, Heidelberg, Germany
[3] German Consortium Translat Canc Res DKTK, Clin Cooperat Unit Neurooncol, Heidelberg, Germany
[4] German Consortium Translat Canc Res DKTK, Heidelberg, Germany
[5] Ludwig Maximilians Univ LMU, Dept Neurosurg, Munich, Germany
[6] Friedrich Alexander Univ Erlangen Nuernberg, Dept Neurosurg, Erlangen, Germany
[7] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Hematol & Oncol Div,Canc Ctr, Boston, MA USA
[8] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Div Neuropathol, Boston, MA USA
[9] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA
[10] Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med, Cellular Immunotherapy Program, Boston, MA USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 12期
关键词：
PRIMARY CNS LYMPHOMA;
D O I：
10.1002/ajh.27505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2411 / 2415
页数：5
相关论文
共 50 条
  • [21] Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
    Hu, Yongxian
    Sun, Jie
    Wu, Zhao
    Yu, Jian
    Cui, Qu
    Pu, Chengfei
    Liang, Bin
    Luo, Yi
    Shi, Jimin
    Jin, Aiyun
    Xiao, Lei
    Huang, He
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [22] Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
    Yongxian Hu
    Jie Sun
    Zhao Wu
    Jian Yu
    Qu Cui
    Chengfei Pu
    Bin Liang
    Yi Luo
    Jimin Shi
    Aiyun Jin
    Lei Xiao
    He Huang
    Journal of Hematology & Oncology, 9
  • [23] CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenstrom Macroglobulinemia: Initial Experience in Two Clinical Trials
    Qualls, David
    Monette, Sebastien
    Sethi, Shenon
    Dogan, Ahmet
    Roshal, Mikhail
    Senechal, Brigitte
    Wang, Xiuyan
    Riviere, Isabelle
    Sadelain, Michel
    Brentjens, Renier
    Park, Jae
    Smith, Eric
    Palomba, M. Lia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S443 - S443
  • [24] Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
    Miyao, Kotaro
    Yokota, Hirofumi
    Sakemura, R. Leo
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [25] CD19-directed chimeric antigen receptor T cell therapy in Waldenstrom macroglobulinemia: a preclinical model and initial clinical experience
    Palomba, M. Lia
    Qualls, David
    Monette, Sebastien
    Sethi, Shenon
    Dogan, Ahmet
    Roshal, Mikhail
    Senechal, Brigitte
    Wang, Xiuyan
    Riviere, Isabelle
    Sadelain, Michel
    Brentjens, Renier J.
    Park, Jae H.
    Smith, Eric L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [26] Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience
    Hashmi, Hamza
    Mirza, Abu-Sayeef
    Darwin, Alicia
    Logothetis, Constantine
    Garcia, Franco
    Kommalapati, Anuhya
    Bachmeier, Christina A.
    Benson, Kaaron
    Chavez, Julio C.
    Shah, Bijal D.
    Pinilla-Ibarz, Javier
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien
    Davila, Marco L.
    Nishihori, Taiga
    Jain, Michael D.
    Locke, Frederick L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S257 - S258
  • [27] Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells
    Evans, Andrew G.
    Rothberg, Paul G.
    Burack, W. Richard
    Huntington, Scott F.
    Porter, David L.
    Friedberg, Jonathan W.
    Liesveld, Jane L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (02) : 205 - 209
  • [28] Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience
    Mirza, Abu-Sayeef
    Hashmi, Hamza
    Darwin, Alicia
    Garcia, Franco
    Kommalapati, Anuhya
    Logothetis, Constantine
    Bachmeier, Christina A.
    Chavez, Julio C.
    Shah, Bijal D.
    Pinilla-Ibarz, Javier
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien
    Davila, Marco L.
    Nishihori, Taiga
    Locke, Frederick L.
    Jain, Michael D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S265 - S266
  • [29] T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy
    Martin, Lisa J.
    Whitmore, James B.
    Shen, Rhine R.
    Neumann, Frank
    BLOOD ADVANCES, 2024, 8 (15) : 4144 - 4148
  • [30] Neurological toxicities associated with chimeric antigen receptor T-cell therapy
    Rubin, Daniel B.
    Danish, Husain H.
    Ali, Ali Basil
    Li, Karen
    LaRose, Sarah
    Monk, Andrew D.
    Cote, David J.
    Spendley, Lauren
    Kim, Angela H.
    Robertson, Matthew S.
    Torre, Matthew
    Smith, Timothy R.
    Izzy, Saef
    Jacobson, Caron A.
    Lee, Jong Woo
    Vaitkevicius, Henrikas
    BRAIN, 2019, 142 : 1334 - 1348
12345